TARS (STOCKS)
Tarsus Pharmaceuticals, Inc. Common Stock
$73.250000
+0.690000 (+0.95%)
Prev close: $72.560000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Bobak Azamian
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $3,087.97M
- Employees
- 323
- P/E (TTM)
- -45.13
- P/B (TTM)
- 9.00
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
7
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.20 | $-0.10 | -0.1030 | -106.19% |
|
Sep 2025 (Q3)
|
$-0.30 | $-0.36 | +0.0574 | +16.06% |
|
Jun 2025 (Q2)
|
$-0.48 | $-0.41 | -0.0724 | -17.76% |
|
Mar 2025 (Q1)
|
$-0.64 | $-0.75 | +0.1052 | +14.12% |
Financial Statements
| Revenues | $451.36M |
| Benefits Costs and Expenses | $515.72M |
| Costs And Expenses | $522.33M |
| Nonoperating Income/Loss | $6.61M |
| Operating Expenses | $522.33M |
| Selling, General, and Administrative Expenses | $427.32M |
| Research and Development | $64.32M |
| Other Operating Expenses | $30.68M |
| Operating Income/Loss | -$70.97M |
| Income/Loss From Continuing Operations After Tax | -$66.42M |
| Income/Loss From Continuing Operations Before Tax | -$64.36M |
| Income Tax Expense/Benefit | $2.06M |
| Income Tax Expense/Benefit, Current | $2.06M |
| Income Tax Expense/Benefit, Deferred | $0.00 |
| Net Income/Loss | -$66.42M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$66.42M |
| Net Income/Loss Available To Common Stockholders, Basic | -$66.42M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.59 |
| Diluted Earnings Per Share | -$1.59 |
| Basic Average Shares | 41,784,014 |
| Diluted Average Shares | 41,784,014 |
| Assets | $562.16M |
| Current Assets | $522.78M |
| Inventory | $4.37M |
| Prepaid Expenses | $13.47M |
| Other Current Assets | $504.94M |
| Noncurrent Assets | $39.38M |
| Fixed Assets | $11.67M |
| Intangible Assets | $7.37M |
| Other Non-current Assets | $20.35M |
| Liabilities | $218.73M |
| Current Liabilities | $135.70M |
| Accounts Payable | $16.39M |
| Wages | $17.78M |
| Other Current Liabilities | $101.53M |
| Noncurrent Liabilities | $83.04M |
| Long-term Debt | $72.44M |
| Other Non-current Liabilities | $10.60M |
| Equity | $343.43M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $343.43M |
| Liabilities And Equity | $562.16M |
| Net Cash Flow From Operating Activities | -$12.45M |
| Net Cash Flow From Operating Activities, Continuing | -$12.45M |
| Net Cash Flow From Investing Activities | -$42.12M |
| Net Cash Flow From Investing Activities, Continuing | -$42.12M |
| Net Cash Flow From Financing Activities | $143.39M |
| Net Cash Flow From Financing Activities, Continuing | $143.39M |
| Net Cash Flow | $88.82M |
| Net Cash Flow, Continuing | $88.82M |
| Comprehensive Income/Loss | -$66.22M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$66.22M |
| Other Comprehensive Income/Loss | $202.00K |